Lonza to manufacture Acumen's monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer's disease (AD)Acumen is on track to initiate a Phase 2 clinical trial evaluating sabirnetug in the first half of 2024 CHARLOTTESVILLE, Va. and BASEL, Switzerland, April ...